CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Rifampicindrug
Likely dose
Rifampicin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01293422
NCT01293422Phase 4Completed
CompareCT.gov

PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon

University of Oulu·interventional·Posted Feb 10, 2011·Updated Sep 10, 2012

In Brief

A Phase 4 clinical trial evaluating Rifampicin for Glucose Metabolism. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This clinical trial is designed to study the effects of pregnane X receptor activator rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the glucose and insulin levels during oral glucose tolerance test.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlucose Metabolism
CountriesFinland
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2011
Enrollment StartJan 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.4 years ago

Interventions

Rifampicindrug

Rifampicin 600 mg daily for a week